FH and renal cell carcinoma: The SHJTUCMRJ study cohort consisted of 252 participants from 16 centers: patients with FH-deficient (FH-MT) RCC spanning the full spectrum of stages (I, II, III and IV; n = 77) were from our established cohort (34); 70 of 77 of the patients with FH-MT carried germline mutations, whereas 7 were sporadic cases involving missense, nonsense, frameshift, and large-scale deletion.